RE: Will this company ever make money for you? No and yes.10 Aug 2024 22:59
They haven't remained silent though have they Doc3? Last interview given by RM to shareholders on 27th June 2024, barely a few weeks ago.
For those who missed it:
"Overview of Synairgen’s work over the past year:
RM: Over the past year, we’ve been reviewing a lot of our clinical trial data so for our drug, SNG001, Which is inhaled anti-viral that we deliver directly into the lungs of patients with the aim of helping them handle common respiratory viral infections. So this would be things like influenza infection, RSV, rhinovirus, and of course more recently SARS, CoV-2 infections. We’ve looked at our data from the trials we conducted before the pandemic and also during the pandemic. And we mapped that against the current medical need - where are the patients that were really suffering when they get these wide range of viruses? And the result of all that, along with interaction with the medical community, has led us to want to start a face to trial in mechanically, ventilated patients.
Why have you chosen mechanically ventilated patients as the target to patient population for the next clinical trial?
RM: There’s two or three reasons around this. Firstly, from a medical need perspective, the mortality for patients who have got one of these viruses in their lungs when they are on a ventilator is in the range of 25 to 45%, and these patients are expensive to treat, so you’ve got a high medical need to treat, a commercial need, and there are very few therapeutic options for these patients. So, medical and commercial take us towards ventilated patients. But there’s also a couple of things that have emerged across the trials we conducted. Pretty much in all the trials, the patients who were most badly affected with the virus when we start treatment (so things like breathlessness, or low oxygen saturations) seem to respond best to drug. And the other thing is, we seem to stop bad things from happening to patients in different settings. And this is encouraging data. So in the outpatient, we seem to lower the risk that patients will become hospitalised. If they’re already hospitalised, we seem to have the signal suggesting that they are less likely to deteriorate further and die. So taking all of that knowledge, plus the clinical need really pushes us towards trying to do something for these ventilated patients in a phase 2 clinical trial.
So what are the next steps, Richard? What can we expect to hear from you next?
RM: So the next updates from us will be more details on the clinical trial we want to start this Winter, so I look forward to seeing you again when I can provide those updates."
Sign In
Follow the stocks
